Tagged with Astellas

Belgium 20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets – outlines the strategic significance of the cluster to the company. Benelux is both a source and recipient of cutting-edge biopharmaceutical…

USA Astellas has steadily developed its immuno-oncology (IO) pipeline via both organic and inorganic means in recent years, with its early-phase IO projects now overseen by industry veteran Peter Sandor, the company’s SVP and IO Primary Focus Lead. Sandor explains the variety of exciting IO approaches in development at Astellas, how…

UAE With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and faster access to cutting-edge biopharmaceutical innovation than ever before. Here, four leading lights in the region’s pharmaceutical industry highlight some of the most important…

UAE Amr Seif outlines Astellas’ progress into becoming a focused oncology speciality player in the Middle East and Africa, in line with the company’s global Corporate Strategic Plan 2021 (CSP2021). He also touches on key market trends in MEA, including regulatory developments, the rise of private insurance, and the growing importance…

LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…

China The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China, how the country’s drug pricing policy is impinging biotech profits, and the ways in which COVID-19 exposed the weaknesses in…

LatAm Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist, LatAm’s rich tradition of democratic participation, and industry stakeholders’ continuously stated commitments to including the patient voice in their decision-making…

Japan In the five years since the Japanese drugmaker began a strategic shift and created an ambitious plan to maintain growth, CEO Kenji Yasukawa helped Astellas move away from its previous business model and bounce back from failing revenues. With the appointment of former chief strategy officer Naoki Okamura as its…

Japan Japan is known for its cutting-edge technology, innovative products, and world-class healthcare system. The pharmaceutical industry in Japan is no exception, with many leading companies making significant contributions to global health and wellness. Read on for a rundown of the top 10 Japanese pharmaceutical companies (based on market capitalisation in…

Egypt Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years – outline how the product launch process has improved and why government stakeholders are more receptive than ever to industry innovations.…

Egypt While evidence and recognition are growing that gender-balanced and diverse management teams at all levels of hierarchies produce positive business outcomes, the MENA region still has a long road to travel in this respect. Only 11 percent of senior management positions in MENA firms and just four percent of board…

Americas In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators in the region, LatAm currently supports about 10 percent of the world’s clinical research. Local industry leaders discuss the advantages…